Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center
Objectives: Therapeutic options for pancreatic neuroendocrine neoplasia (Pan-NEN) have increased over the last decade. We aim to understand the evolution of the prognosis of patients with diagnosis of Pan-NEN within a 12-year period, considering the implementation of new treatments. Methods: This...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2023-01-01
|
| Series: | Endocrine Oncology |
| Subjects: | |
| Online Access: | https://eo.bioscientifica.com/view/journals/eo/2/1/EO-22-0043.xml |
| _version_ | 1828067014054248448 |
|---|---|
| author | Sara Coelho Cláudia Costa Ana Paula Santos Pedro Souteiro Joana Oliveira Isabel Azevedo Isabel Torres Maria José Bento |
| author_facet | Sara Coelho Cláudia Costa Ana Paula Santos Pedro Souteiro Joana Oliveira Isabel Azevedo Isabel Torres Maria José Bento |
| author_sort | Sara Coelho |
| collection | DOAJ |
| description | Objectives: Therapeutic options for pancreatic neuroendocrine neoplasia (Pan-NEN) have increased over the last decade. We aim to understand the evolution of the prognosis of patients with diagnosis of Pan-NEN within a 12-year period, considering the implementation of new treatments.
Methods: This study is a retrospective cohort study of patients diagnosed with Pan-NENs between 2006 and 2017. Survival outcome estimates were calculated by Kaplan–Meier method. The impact of baseline clinicopathological characteristics on survival was explored with the use of Cox proportional hazard model.
Results: Of the 97 patients, 77 (79.9%) had well-differentiated neuroendocrine tumor (NET) according to WHO 2010 classification, and 52 (53.6%) had l ocalized or locoregional disease. There were no differences between clinicopathological characteristics and survival outcomes when comparing patients diagnosed between 2006–2011 and 2012–2017. Neuroendocrine carcinoma – HR 2.76, 95% CI 1.17–6.55 – and stages III and IV at diagnosis were independent poor prognostic factors – HR 6.02, 95% CI 2.22–16.33 and HR 6.93, 95% CI 2.94–16.32, respectively.
Conclusions: The new therapeutic approaches did not induce better survival outcomes on Pan-NEN in recent years. This is possibly due to the indolent nature of NET grades 1 and 2, even metastatic, allowing patients to be submitted to new target therapies along their disease course. |
| first_indexed | 2024-04-10T23:39:45Z |
| format | Article |
| id | doaj.art-d1a78820592c461aa1a4223c7d52822a |
| institution | Directory Open Access Journal |
| issn | 2634-4793 |
| language | English |
| last_indexed | 2024-04-10T23:39:45Z |
| publishDate | 2023-01-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Oncology |
| spelling | doaj.art-d1a78820592c461aa1a4223c7d52822a2023-01-11T12:36:40ZengBioscientificaEndocrine Oncology2634-47932023-01-01213241https://doi.org/10.1530/EO-22-0043Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive centerSara Coelho0Cláudia Costa1Ana Paula Santos2Pedro Souteiro3Joana Oliveira4Isabel Azevedo5Isabel Torres6Maria José Bento7Department of Medical Oncology, Portuguese Oncology Institute of Porto, EPE, Porto, PortugalDepartment of Endocrinology, Portuguese Oncology Institute of Porto, EPE, Porto, PortugalDepartment of Endocrinology, Portuguese Oncology Institute of Porto, EPE, Porto, Portugal; Research Center, Portuguese Oncology Institute of Porto, EPE, Porto, PortugalDepartment of Endocrinology, Portuguese Oncology Institute of Porto, EPE, Porto, PortugalDepartment of Medical Oncology, Portuguese Oncology Institute of Porto, EPE, Porto, PortugalDepartment of Medical Oncology, Portuguese Oncology Institute of Porto, EPE, Porto, PortugalDepartment of Endocrinology, Portuguese Oncology Institute of Porto, EPE, Porto, PortugalDepartment of Epidemiology, Portuguese Oncology Institute of Porto, EPE, Porto, Portugal; School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal Objectives: Therapeutic options for pancreatic neuroendocrine neoplasia (Pan-NEN) have increased over the last decade. We aim to understand the evolution of the prognosis of patients with diagnosis of Pan-NEN within a 12-year period, considering the implementation of new treatments. Methods: This study is a retrospective cohort study of patients diagnosed with Pan-NENs between 2006 and 2017. Survival outcome estimates were calculated by Kaplan–Meier method. The impact of baseline clinicopathological characteristics on survival was explored with the use of Cox proportional hazard model. Results: Of the 97 patients, 77 (79.9%) had well-differentiated neuroendocrine tumor (NET) according to WHO 2010 classification, and 52 (53.6%) had l ocalized or locoregional disease. There were no differences between clinicopathological characteristics and survival outcomes when comparing patients diagnosed between 2006–2011 and 2012–2017. Neuroendocrine carcinoma – HR 2.76, 95% CI 1.17–6.55 – and stages III and IV at diagnosis were independent poor prognostic factors – HR 6.02, 95% CI 2.22–16.33 and HR 6.93, 95% CI 2.94–16.32, respectively. Conclusions: The new therapeutic approaches did not induce better survival outcomes on Pan-NEN in recent years. This is possibly due to the indolent nature of NET grades 1 and 2, even metastatic, allowing patients to be submitted to new target therapies along their disease course.https://eo.bioscientifica.com/view/journals/eo/2/1/EO-22-0043.xmlneuroendocrine tumorspancreatic cancertumor gradingneoplasm stagingprognostic factors |
| spellingShingle | Sara Coelho Cláudia Costa Ana Paula Santos Pedro Souteiro Joana Oliveira Isabel Azevedo Isabel Torres Maria José Bento Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center Endocrine Oncology neuroendocrine tumors pancreatic cancer tumor grading neoplasm staging prognostic factors |
| title | Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center |
| title_full | Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center |
| title_fullStr | Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center |
| title_full_unstemmed | Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center |
| title_short | Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center |
| title_sort | pancreatic neuroendocrine neoplasms survival trend analysis of a comprehensive center |
| topic | neuroendocrine tumors pancreatic cancer tumor grading neoplasm staging prognostic factors |
| url | https://eo.bioscientifica.com/view/journals/eo/2/1/EO-22-0043.xml |
| work_keys_str_mv | AT saracoelho pancreaticneuroendocrineneoplasmssurvivaltrendanalysisofacomprehensivecenter AT claudiacosta pancreaticneuroendocrineneoplasmssurvivaltrendanalysisofacomprehensivecenter AT anapaulasantos pancreaticneuroendocrineneoplasmssurvivaltrendanalysisofacomprehensivecenter AT pedrosouteiro pancreaticneuroendocrineneoplasmssurvivaltrendanalysisofacomprehensivecenter AT joanaoliveira pancreaticneuroendocrineneoplasmssurvivaltrendanalysisofacomprehensivecenter AT isabelazevedo pancreaticneuroendocrineneoplasmssurvivaltrendanalysisofacomprehensivecenter AT isabeltorres pancreaticneuroendocrineneoplasmssurvivaltrendanalysisofacomprehensivecenter AT mariajosebento pancreaticneuroendocrineneoplasmssurvivaltrendanalysisofacomprehensivecenter |